A recent phase I dose escalation clinical trial in melanoma has shown that another HSP90 inhibitor (XL888) in combination with a specific anti BRAF inhibitor (vemurafenib) has clinical activity in patients with advanced BRAFV600-mutant melanoma, with a tolerable side effect profile [65]. Here, BRAF is linked to melanoma.